Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma and High-Grade Glioma

Trial Profile

Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma and High-Grade Glioma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Crizotinib (Primary) ; Dasatinib (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.
    • 31 Jan 2018 Planned End Date changed from 1 Oct 2020 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top